A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of C-Met and Vascular Endothelial Growth Factor Receptor 2
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-10-0574
Full Text
Open PDFAbstract
Available in full text
Date
May 14, 2010
Authors
Publisher
American Association for Cancer Research (AACR)